版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、 0.01 mm0.01 mm C D Kolandaivelu et al 2011 Thin Struts allow for Low blood flow perturbance Easy struts nesting to the vessel wall Added flexibility and conformability Improved, faster endothelialization Improved clinical outcome Strut thickness Cypher 140 m Taxus 132 m Endeavor 91 m Xience V 81 m
2、Element 81 m X 500 50mm 12 57 DES Synergy 74 m X 500 50mm 12 57 DES Low Strut Thickness with Potential to minimize vessel injury Platinum-ChromiumPlatinum-ChromiumStainless SteelStainless SteelCobalt-ChromiumCobalt-Chromium 2.6% Molybdenum Nickel Composition (by weight (%) Element Stent Series Radia
3、l Strength CoCr AlloyPtCr Alloy Element Stent Series Minimize Recoil CoCr AlloyStainless Steel Alloy Stainless Steel Alloy Conformability Measures the ability of the stent to naturally conform to the vessel Stent Models and optimal drug Elution 4 Stent Models for consistent stent to artery ratios, a
4、nd uniform drug delivery ModelDiameter SV2.25 mm SWH2.50 mm SWH2.75 mm WH3.00 mm WH3.50 mm LV4.00 mm ModelDiameter Small2.25 mm Small2.50 mm Small2.75 mm Small3.00 mm Medium3.50 mm Medium4.00 mm ModelDiameter Small2.25 mm Small2.50 mm Small2.75 mm Medium3.00 mm Medium3.50 mm Medium4.00 mm PROMUS Ele
5、ment Stent 4 Stent Models Xience V Meredith, et al. Eurointervention 2011;7:84. SPIRIT III: Stone, et al. JAMA. 2008;299:1903. Results from different studies are not directly comparable. Information provided for educational purposes only. Post-Procedure Incomplete Stent Apposition p 0.001 Late Incom
6、plete Stent Apposition PLATINUM QCA Trial* PLATINUM QCA Trial 9-Month Results (n = 90)(n =88)(n = 90) PLATINUM QCA Study Incomplete Stent Apposition Results in Perspective 83% Reduction SPIRIT III Trial SPIRIT III Trial 8-Month Results ENDEAVOR II Trial# 8-Month Results ENDEAVOR II Trial# *PLATINUM
7、QCA Trial; Meredith, et al. Eurointervention 2011;7:84. SPIRIT III: Stone, et al. JAMA. 2008;299:1903. #ENDEAVOR II: Endeavor DFU. RESOLUTE: Circulation Journal Aug 3, 2010. SPIRIT Clinical Trials are sponsored by Abbott. Results from different studies are not directly comparable. Information provid
8、ed for educational purposes only. PLATINUM QCA Trial*RESOLUTE Trial Acute Incomplete Stent Apposition (%) Late Incomplete Stent Apposition (%) SPIRIT Prime Trial Not Reported Not Reported PROMUS Element Stent Endeavor Stent Xience V Stent Resolute Stent Xience Prime Stent (n =90) (n = 90)(n = 81) (n
9、 = 69) (n = 104)(n = 88) PROMUS Element Stent Endeavor Stent Xience V Stent Resolute Stent Xience Prime Stent PLATINUM QCA Trial* 9-Month Results RESOLUTE Trial 8-Month Results SPIRIT Prime Trial (n = 145) (n = 125) PLATINUM QCA Trial Incomplete Stent Apposition results in perspective Presented by G
10、regg W. Stone, MD, ACC 2012. Study Objective: Evaluate the safety and effectiveness of the PROMUS Element Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions compared to the Xience V Stent. Study Design:Prospective, rand
11、omized, controlled, single-blind, non-inferiority trial in patients with up to 2 de novo target lesions; lesion length 24 mm; reference vessel diameter 2.50 4.25 mm. Primary Endpoint:Target Lesion Failure (Ischemia-Driven TLR, target vessel MI, or target vessel cardiac death) at 12 months. Additiona
12、l Endpoints:Components of TLF and ARC ST (Def/Prob), Technical Success, Clinical Procedural Success. Patient Population*: PROMUS Element Stent n = 758 Xience V Stentn = 749 Number of Sites:132 (U.S., EU, Japan ACC 2012 PLATINUM Workhorse Clinical Trial 2-Year Clinical Results * Patients who received
13、 a study stent. TLF=Ischemia-driven (ID) target lesion revascularization (TLR), cardiac death related to the target vessel (TV) or myocardial infarction (MI) related to the TV. Presented by Gregg W. Stone, MD, ACC 2012. *Not presented, BSC data on file. Incidence Rate (%) p = 0.28p = 0.12 p= 0.98 Co
14、mponents of TLF PROMUS Element Stent (n = 758) Xience V Stent (n = 749) p = 0.32 Primary endpoint was TLF at 1-year *TLF=Ischemia-driven (ID) target lesion revascularization (TLR), cardiac death related to the target vessel (TV) or myocardial infarction (MI) related to the TV. TVR: target vessel rev
15、ascularization. ST: stent thrombosis. Incidence Rate (%) p = 0.30 p = 0.12 p = 0.54 p = 0.15 p = 0.80 PROMUS Element Stent (n = 758) Xience V Stent (n = 749) p = 0.99 PROMUS Element Stent demonstrated numerically lower events p = 0.33p = 0.32 Presented by Gregg W. Stone, MD, ACC 2012. Significant Re
16、duction in Bail-out Stenting Incidence Rate (%) p = 0.004p = 0.36 p = 0.01p = 0.06 PROMUS Element Stent (n = 768) Xience V Stent (n = 762) Overall RateCited Reason for Bail-out Stent PLATINUM Workhorse Trial: Stone, et al. JACC 2011; 57:1700. Intent to Treat Analysis. PLATINUM Workhorse Clinical Tri
17、al Peri-procedural Unplanned Bail-Out Stenting Target Lesion Failure (%) Months Since Index Procedure 2-Year Landmark Analysis TLF = cardiac death or MI related to the target vessel or ischemia-driven TLR; Patients with Study Stents. 3691215182124 3.0% 1.2% 1-yr HR 95% CI = 1.12 0.63, 1.99 P = 0.70
18、0 Treatment GroupPROMUS Element 1Y PROMUS 1Y PROMUS Element 1-2Y PROMUS 1-2Y 3.3% 3.0% 1-yr to 2-yr HR 95% CI = 0.44 0.20, 0.97 P = 0.04 CoCr-EES (N=749 at time 0, n=722 at 1 year) PtCr-EES (N=758 at time 0, n=736 at 1 year) Ischemia-Driven TLR (%) Months Since Index Procedure 2-Year Landmark Analys
19、is 3691215182124 CoCr-EES (N=749 at time 0, n=722 at 1 year) PtCr-EES (N=758 at time 0, n=736 at 1 year) 1-yr HR 95% CI = 0.98 0.47, 2.07 P = 0.97 0 1-yr to 2-yr HR 95% CI = 0.33 0.12, 0.90 P = 0.02 Treatment GroupPROMUS Element 1Y PROMUS 1Y PROMUS Element 1-2Y PROMUS 1-2Y 2.2% 0.7% 1.9% 1.9% TLR =
20、target lesion revascularization CoCr (%) PtCr (%) Relative Risk (95% CI) Relative Risk (95% CI) P Interaction All randomized (n=1507)5.8%4.6%0.78 (0.50-1.22)0.28 Age 65.0 yrs (n=779)7.0%3.9%0.55 (0.29-1.03) 0.10 Age 65.0 yrs (n=728)4.4%5.3%1.20 (0.61-2.36) Male (n=1074)4.8%4.5%0.93 (0.53-1.63) 0.30
21、Female (n=433)8.4%4.8%0.57 (0.27-1.22) Diabetic (n=351)7.9%5.9%0.75 (0.34-1.69) 0.86 Nondiabetic (n=1156)5.1%4.2%0.82 (0.48-1.40) Single vessel Tx (n=1399)6.0%4.5%0.76 (0.48-1.20) 0.56 Dual vessel Tx (n=108)4.1%5.3%1.29 (0.22-7.41) BMI 2.62 mm (n=728)5.3%3.6%0.67 (0.33-1.35) Lesion 13.0 mm (n=870)5.
22、3%4.2%0.79 (0.43-1.45) 0.94 Lesion 13.0 mm (n=636)6.6%5.0%0.76 (0.40-1.47) TLF at 2 Years PtCr betterCoCr better 102 Binary Rates Presented by Dominic Allocco, MD, PCR 2012. Ian T. Meredith MBBS, PhD is the PI. Study Objective: Evaluate the safety 2.25 mm to 24 and 34 mm in length, 2.50 mm to 4.25 m
23、m in diameter Study Design:Prospective, single-arm, multi-center Primary Endpoint:12-month TLF (ID-TLR or TV-CD or TV-MI) against a performance goal of 19.4% (based on historical TAXUS Express results) in the per protocol population Number of Patients: PROMUS Element Stent n = 102 Number of Sites:30
24、 sites (U.S., Australia, New Zealand, Belgium, France, Japan, Latvia) Presented by Paul S. Teirstein, MD, TCT 2011. PROMUS Element and TAXUS Express are trademarks of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners. This material is n
25、ot intended for the U.S. or Japan. Please see glossary. * Intent-to-treat population. Results from different clinical trials are not directly comparable. Information provided for educational purposes only. *PROMUS Element has a dedicated small vessel 2.25mm stent model. Xience V is the 2.50-3.00 mm
26、model crimped to a 2.25mm balloon. #PLATINUM SV Presented by Ian T. Meredith, MBBS, PhD, PCR 2011. +Xience DFU. The SPIRIT Clinical Trials are sponsored by Abbott. -RESOLUTE US Trial, Leon, et al. JACC 2011; 57;1778-1783. Resolute is a trademark of Medtronic Vascular, Inc. This material is not inten
27、ded for the U.S. or Japan. Please see glossary. * Xience PRIMEis ARC to protocol . Presented at 2011TCT by Marco A,Costa MD* Resolute Long DES IV based on protocol analysis , presented at 2011TCT by Seung Jung Park. SPIRIT Prime Long Lesion Trial*+ Xience Prime Stent (n = 136) RVD = 2.13 mm Lesion Length = 13.38 mm PLATINUM Long Lesion Trial*# PROMUS Element Stent* RVD = 2.56 mm Lesion Length = 24.38 mm (n = 102) Incidence rates % Incidence rates % Resolute Long DES IV Trial*- Resolute Stent* (n = 250) Incidence rates %
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 皮亚杰认知发展阶段理论在小学数学教学中的应用-《认识垂线》教学探索 论文
- 小学语文阅读创新教学策略探讨 论文
- 2022年数学六年级上册期末考试试卷【考点精练】
- 2022人教版六年级上册数学 期末测试卷附答案【巩固】
- 人教版六年级上册数学期中考试试卷含解析答案
- 2022人教版数学三年级上册期中考试试卷附答案(a卷)
- 人教版三年级上册数学期末测试卷附参考答案(b卷)
- 一年级20以内加减法计算题50道含答案【满分必刷】
- 人教版四年级下册数学第六单元《小数的加法和减法》测试卷附参考答案(黄金题型)
- 人教版六年级下册数学期末测试卷及答案【新】
- 几百部英文电影mp3(附字幕_英语学习绝佳材料_强烈推荐)
- 气胸的护理查房
- 【2020-2021自招】福建福州第三中学初升高自主招生数学模拟试卷【4套】【含解析】
- 人教版四年级数学下册第四单元整理和复习
- 《四通八达的交通》教案及反思
- 学习国旗法幻灯片(课堂PPT)
- 电池片转换效率和功率换算
- (实训项目十二) 柴油机气阀间隙检查和调整
- GB_T 37821-2019 废塑料再生利用技术规范(高清版)
- 农行对账单流水单英文翻译签证用
- 华成多轴机械手控制系统说明书V
评论
0/150
提交评论